In 1968, IMS began business with the
launch of unit dose emergency drugs. Over the years, the
company continued its growth through the licensing of
their products to major manufacturers of drugs and
health care products.
In 1998, Amphastar
acquired IMS from Medeva, PLC, a London based
pharmaceutical company. Under Amphastar's management,
IMS experienced tremendous growth in research and
IMS is a federally registered manufacturer of sterile injectable pharmaceuticals. These sterile injectables are
used with a wide variety of IMS delivery systems,
including prefilled syringes and vials.
IMS maintains an excellent
regulatory/cGMP compliance record and has a wealth of
experience in dealing with Federal,
and local regulatory agencies. Our facilities are
registered and inspected regularly by the United
States Food and Drug Administration (FDA),
the United States Drug Enforcement Agency (DEA), and the
California State Food and Drug Board.